<DOC>
	<DOCNO>NCT01254123</DOCNO>
	<brief_summary>Myocardial infarction ( MI ) cause loss myocytes may lead loss ventricular function , morbidity mortality . The effective therapy early reperfusion ischemic myocardium percutaneous coronary intervention ( PCI ) . Reperfusion limit myocardial ischaemic necrosis , also induce inflammation , oxidative stress calcium overload : process refer reperfusion injury lead necrosis apotosis . Glucagon Like Peptide-1 ( GLP-1 ) incretin hormone show activate anti-apoptotic enzyme , reduce reperfusion injury . GLP-1 agonist demonstrate cardioprotective several animal study single small non-randomized clinical study . In pilot study assess safety efficacy GLP-1 receptor agonist Exenatide infusion compare placebo patient acute myocardial infarction undergo primary PCI . A total 40 patient include single centre prospective randomise placebo control two-arm pilot study . Patients undergo primary PCI first acute ST elevation myocardial infarction randomly assign placebo Exenatide 5ug bolus 30 minute , follow continuous Exenatide infusion 20ug/ 24 hour 72 hour . Blood sample obtain assessment enzymatic infarct size Exenatide level . Side effect Exenatide stringently monitor . Cardiac function measure use Cardiac Magnetic Resonance Imaging ( CMRI ) 3D echocardiography 1 week 4 month post MI . Infarct size assess mean final infarct size 4 month post MI percentage area risk 1 week post MI . Furthermore compare RNA profile group .</brief_summary>
	<brief_title>Effect Additional Treatment With EXenatide Patients With Acute Myocardial Infarction ( EXAMI Trial )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>&gt; 18 &lt; 80 year age First myocardial infarction ST elevation one mm least 2 separate lead electrocardiogram ( ECG ) Delay onset sustain chestpain PCI &lt; 6 hour . Cardiac rhythm normal sinus rhythm . Patient Killip class 3 4 heart failure Cardiogenic shock define sustain systolic blood pressure â‰¤ 80mmHg despite fluid hydration . Post cardiac resuscitation Need intra aortic balloon counterpulsation therapy The patient unable hold his/her breath 20 second due age concomitant illness No former PCI perform No recanalisation achieve occluded coronary artery Culprit segment 1,2,3,6,7,11,12,13 coronary artery No definite culprit More one occluded vessel , 70 % stenosis visual assessment nonculprit vessel . TIMI 3 flow culprit lesion presentation Decreased renal function eGFR &lt; 30ml/min Any contraindication MRI ie : implant electronic device pacemaker , internal defibrillator , neurostimulators , implant drug infusion device , cochlear implant , cerebrovascular clip , claustrophobia . previous vascular surgery : aneurysm clip , carotid artery vascular clamp , aortic clip , venous umbrella spinal/intraventricular shunt Metal fragment eye , head , ear , skin shoulder . SwannGanz catheter . Known preexisting leave ventricular dysfunction measure technique ( ejection fraction &lt; 45 % prior current admission myocardial infarction ) Prior myocardial infarction Prior coronary artery bypass graft Moderate severe cardiac valve disease Stroke transient ischemic attack within previous 24 hour Serious know concomitant disease life expectancy le one year Follow impossible Previous participation trial within previous 30 day Known type I Diabetes Mellitus Known type II Diabetes Mellitus Pregnancy and/or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Glucagon Like Peptide-1</keyword>
	<keyword>Exenatide</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>MRI</keyword>
	<keyword>PCI</keyword>
</DOC>